Celsion Corp
Change company Symbol lookup
Select an option...
CLSN Celsion Corp
PSA-M Public Storage
BDX Becton Dickinson and Co
GGN GAMCO Global Gold, Natural Resources & Income Trust
GUT Gabelli Utility Trust
CHD Church & Dwight Co Inc
CHY Calamos Convertible & High Income Fund
CHW Calamos Global Dynamic Income Fund
CCVIX Calamos Convertible Fund Class A
ETY Eaton Vance Tax-Managed Diversified Equity Income Fund
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Value
Company profile

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).

Closing Price
$2.06
Day's Change
-0.14 (-6.36%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.20
Day's Low
1.98
Volume
(Light)
Volume:
6,712,857

10-day average volume:
49,382,278
6,712,857

Upcoming Events

CLSN's fiscal year ends in December
There are no upcoming events for CLSN

Past Earnings

This page reports .
DateEvent descriptionEarnings per
share actual
Earnings
estimate range
Previous year's
actual
November 16, 2020Q3 2020 Earnings Release-$0.24-$0.18 to -$0.08-$0.25
August 14, 2020Q2 2020 Earnings Release-$0.18-$0.20 to -$0.10-$0.29
May 15, 2020Q1 2020 Earnings Release-$0.20-$0.21 to -$0.13-$0.12
March 25, 2020Q4 2019 Earnings Release-$0.10-$0.34 to -$0.10--

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

, , , Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.